Document:

Exhibit 10.7

 

ASSIGNMENT AGREEMENT

 

This
Assignment Agreement (the “Agreement”) is made as of March 15, 2016 (the “Effective Date”), by and between
Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Tallikut”), and Accelerated Pharma,
Inc., a corporation organized under the laws of Delaware (“API”).

 

RECITALS

 

WHEREAS, Tallikut owns the right, title
and interest in and to all assets related to picoplatin including licensed rights to the AnorMED patents (the “Picoplatin
Assets”); and

 

WHEREAS API is desirous of acquiring the entire right,
title and interest in the same.

 

NOW, THEREFORE, in consideration of the
above recitals and the mutual covenants hereinafter set forth, API and Tallikut, intending to be legally bound, hereby agree as
follows:

 

		1.	Assignment. Tallikut agrees to sell, assign, transfer
and convey to API all of Tallikut’s right, title and interest in and to all of the following (collectively, the “Property
Rights”):

 

1.1. the worldwide rights,
title and interest in and to any and all trade names, trademark rights, trademarks and service marks (including any and all registrations,
licenses, applications and common law marks pertaining thereto), used in connection with the Picoplatin Assets, together with (a)
the goodwill of the Picoplatin Assets associated therewith and symbolized by same and (b) all common law rights therein and the
right to sue for past infringement of any and all of said trademarks (collectively, the “Trademarks”);

 

1.2. all worldwide rights,
title and interest of Tallikut in and to the designs, processes, drawings, schematics, copyrights and copyright applications, if
any, inventions, processes, know-how, trade secrets, patents (including any and all letter patents) patent applications (including
any Patent Cooperation Treaty patent applications and corresponding National patent applications) and other proprietary information
related to the Picoplatin Assets, including, without limitation, any registered copyrights,
patents and copyright and patent applications identified on Exhibit E, and in and to all substitutions, divisions, continuations,
continuationsin-part, reexaminations, extensions, renewals and reissues (as applicable) thereof, and including without limitation
of generality, all rights of priority resulting from the filing of patent applications relating to any of the foregoing as well
as any and all choses in action and any and all claims and demands, both at law and in equity, that Tallikut has or may have for
damages or profits accrued or to accrue on account of the infringement of any patents, patent applications, letter patents, inventions,
improvements and discoveries (or any provisional rights therein), the same to be held and enjoyed by API, its successors and assigns,
as fully and entirely as the same would have been held and enjoyed by Tallikut if the assignment set forth herein had not occurred,
the full and complete right to file patent applications on the aforesaid inventions, improvements, discoveries and applications
in all countries of the world and the entire right, title and interest in and to any letter patent which may issue thereon in the
United States or in any country, and any and all renewals, revivals, reissues, reexaminations and extensions thereof, and any patents
of confirmation, registration and importation of the same (collectively, the “Intellectual Property Rights”);

 

    	 	 	 

     

    

 

1.3. all files, lists, publications,
and other records and data of Tallikut used in or relating to the Picoplatin Assets, regardless of the medium on which such information
is stored and maintained; and

 

1.4. all rights in and to any
governmental and private permits, licenses, and authorizations, to the extent assignable, used in or relating to the Picoplatin
Assets.

 

2.    Title
Passage. Upon the Effective Date, title to all of the Property Rights shall pass to API. Tallikut shall, upon API’s request,
execute any assignments, conveyances and/or bills of sale required to assign, transfer, set over, convey, assure and confirm unto
and vest in API, its successors and assigns, title to all of the Property Rights, as well as such other instruments of conveyance
as counsel for API may reasonably deem necessary to effect or evidence the transfers contemplated hereby.

 

3.    Purchase
Price. The aggregate consideration for the sale, transfer, conveyance and assignment of all the Property Rights to API shall
be $1 (the “Purchase Price”), receipt of which is hereby acknowledged.

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the parties hereto have
duly executed this Assignment Agreement on the dates indicated below.

 

	TALLIKUT PHARMACEUTICALS, INC.	 	ACCELERATED PHARMA, INC.
	 	 	 
	By 	/s/ Fred Craves	 	By:	/s/ Michael Fonstein
	 	 	 	 	 
	Name:  	Fred Craves	 	Name:	Michael Fonstein
	 	 	 	 	 
	Title:  	Chairman of the Board	 	Title:  	Chief Executive Officer
	 	 	 	 	 
	Date:	3/15/16	 	Date:	3/15/16

 

State of _________________________________

County of________________________________

 

ACKNOWLEDGMENT

 

On this________day of March, in the year 2016,
before me, the undersigned, personally appeared Fred Craves, the Chairman of the Board of Tallikut Pharmaceuticals, Inc., a
corporation organized under the laws of Delaware, personally known to me or proved to me on the basis of satisfactory
evidence to be the person who executed the within Assignment Agreement in his or her capacity behalf of said corporation and
acknowledged to me that he or she executed the same for the purposes therein stated.

 

Seal:

 

Notary Public____________________________

My commission expires:

 

[SIGNATURE PAGE TO ASSIGNMENT AGREEMENT]

 

    	 	3	 

     

    

 

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

 

 

	State of California	
	 
	County of   San Francisco                                                   

 

	On	3/15/16	   before me,	M. A. Josephson
	 	Date	 	Here Insert Name and Title of the Officer

 

	Personally appeared 	/s/ Fred Craves
	 	Name(s) of Signer(s)
	 	 
	 	 

 

	 	who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.
	 
	I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.
	 	 
	 	WITNESS my hand and official seal.
	 	 
	 	Signature	/s/ M. A. Josephson
	Place Notary Seal above	 	Signature of Notary Public

 

	OPTIONAL

 

Though the information below is not required
by law, it may prove valuable to persons relying on the document

and could prevent fraudulent removal and reattachment of this form to another document.

 

	Description of Attached Document

 

	Title or Type of Document:	 

 

	Document Date:	 	Number of Pages:	 

 

	Signer(s) Other Than Named Above:	 

 

Capacity(ies) Claimed by Signer(s

 

	Signer’s Name: ______________________	 	 	Signer’s Name: _________________________
	 ̈ Individual 	 	 	 ̈ Individual 
	 ̈ Corporate Officer — Title(s): ________	 	 	 ̈ Corporate Officer — Title(s): ____________
	 ̈ Partner —  ̈ Limited  ̈ General	 	 	 ̈ Partner —  ̈ Limited  ̈ General

	 ̈ Attorney in Fact 	 	 	 ̈ Attorney in Fact 	 
	 ̈ Trustee 	 ̈ Trustee 
	 ̈ Guardian or Conservator	 ̈ Guardian or Conservator
	 ̈ Other: _______________________	 ̈ Other: ____________________
	_______________________________	____________________________
	Signer Is Representing: ____________	Signer Is Representing: _________
	______________________________	____________________________
	______________________________	____________________________

 

 

 

©2007 National Notary Association• 9350 De Solo Ave., P.O.
Box 2402 *Chatsworth. CA 91313.2402 • www NationalNotary.org Item #5907 Reorder:Call Toll-Free 1-800-876-6827

 

    	 	4	 

     

    

 

EXHIBIT E

 

Intellectual Property Rights

 

	 	 	 	 	Application No.

or Registration

No.	 	Application Filing

Date or Registration
	Patent	 	Country	 	as applicable)	 	Date
    (as applicable)
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/857,067	 	11/6/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/877,515	 	12/28/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/927,347	 	5/3/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/931,309	 	5/22/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	 	US	 	60/969,441	 	8/31/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATTN TO TREAT SMALL CELL LUNG CANCER	 	US	 	12/508,392	 	7/23/2009
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	 	US	 	60/857,017	 	11/6/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	 	US	 	60/857,564	 	11/8/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	 	US	 	60/877,570	 	12/28/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATTN TO TREAT PROSTATE CANCER	 	US	 	60/889,179	 	2/9/2007

 

    	 	5	 

     

    

 

	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	60/890,950	 	2/21/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	60/931,609 	 	5/24/2007 
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	60/952,440 	 	7/27/2007 
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	11/935,979	 	11/6/2007 
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF COLORECTAL CANCER	 	US	 	60/857,066	 	11/6/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF COLORECTAL CANCER	 	US	 	60/857/725	 	11/8/2006
	 	 	 	 	 	 	 
	A METHOD OF TREATMENT OF COLORECTAL CANCER	 	US	 	60/877,495	 	12/28/2006
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	60/889,191	 	2/9/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	60/931,589	 	5/24/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	60/683,852	 	10/30/2007
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	12/367,394	 	2/6/2009

 

    	 	6	 

     

    

 

	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	121464,662	 	5/12/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	121465,563	 	5/13/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	12/508,372	 	7/23/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	PCT	 	PCT/U52010/34593	 	5/12/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	 	US	 	13/319,852	 	11/10/2011
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	60/889,201	 	2/912007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	60/889,675	 	2/13/2007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLAT1N	 	US	 	60/984,156	 	10/31/2007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	60/989,020	 	11/19/2007
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	PCT	 	PCT/U52008/00174 6	 	2/8/2009
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	US	 	12/536,311	 	8/5/2009

 

    	 	7	 

     

    

 

	 	 	 	 	Application No.

or Registration

No.	 	Application Filing

Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	ENCAPSULATED PICOPLATIN	 	AU	 	2008214199	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	BR	 	PI 0806362-1	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	CA	 	2,677,639	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	CN	 	200880011347.9	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLAHN	 	EG	 	1200/2009	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLAHN	 	EP	 	08725387.8	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	 	 	10102719.4	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	ID	 	W-00200902208	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	IL	 	200261	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	N	 	5257/CHENP/2009	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	JP	 	2009-549126	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	KR	 	10-2009-7018781	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	MX	 	MX/s/2009/008487	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	PH	 	1-2009-501520	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	RU	 	2009133447	 	2/8/2008
	 	 	 	 	 	 	 
	ENCAPSULATED PICOPLATIN	 	UA	 	200909261	 	2/8/2008

 

    	 	8	 

     

    

 

	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	ENCAPSULATED PICOPLATIN	 	VN	 	1-2009-01904	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORMS	 	US	 	60/889,171	 	2/9/2007
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	US	 	60/889,681	 	2/13/2007
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	PCT	 	PCT/US2008/00175 2	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	US	 	12/536,335	 	8/5/2009
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	AU	 	2008214202	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	BR	 	0806418-0	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	CA	 	2,677,640	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	CN	 	200880011357.2	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	EG	 	1201/2009	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	EP	 	08725393.6	 	2/8/2008

 

    	 	9	 

     

    

 

	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	HK	 	10106157.4	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	ID	 	W-00200902207	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	IL	 	200262	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	IN	 	5256/CHENP/2009	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLAT1N ORAL DOSAGE FORM*	 	JP	 	2009-549128	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLAT1N ORAL DOSAGE FORM*	 	KR	 	10-2009-7018780	 	2/8/208
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	MX	 	MX/a/2009/008488	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	PH	 	1-2009-501521	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	RU	 	2009133446	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	 	UA	 	200909262	 	2/8/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLAT1N ORAL DOSAGE FORM AND	 	VN	 	1-2009-01903	 	2/8/2008

 

    	 	10	 

     

    

 

	Patent	 	Country	 	
        Application No.

        or Registration

        No.

        (as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	PROCESS FOR  PREPARING THE  SAME*	 	 	 	 	 	 
	 	 	 	 	 	 	 
	STABILIZED INTRAVENOUS DOSAGE FORM	 	US	 	60/949,639	 	6/27/2007
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	US	 	60/950,033	 	7/16/2007
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLAT1N	 	US	 	61/043,962	 	4/10/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	PCT	 	PCT/U S2008/008669	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	US	 	12/669,274	 	1/15/2010
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLAT1N	 	CA	 	2,693,057	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLAT1N	 	CN	 	200880103323.6	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	EP	 	08780206.2	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	I-1K	 	11101572.1	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	.1P	 	2010-517010	 	7/16/2008
	 	 	 	 	 	 	 
	ORAL FORMULATION FOR PICOPLATIN	 	TW	 	097127053	 	7/16/2008
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	US	 	61/027,387	 	2/8/2008

 

    	 	11	 

     

    

 

	Patent	 	Country	 	
        Application No.

        or Registration

        No.

        (as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	PCT	 	PCT/U52009/00077 0	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	US	 	12/866,702	 	11/11/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	AU	 	2009210654	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	CA	 	2,715,348	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND 13EVACIZUMAB TO TREAT COLORECTAL CANCER	 	UN	 	200980109758.6	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	EP	 	09708527.8	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	HK	 	11109428.0	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	JP	 	2010-545883	 	2/6/2009

 

    	 	12	 

     

    

 

	Patent	 	Country	 	Application No.

or Registration

No.

(as applicable)	 	Application Filing

Date or Registration

Date (as applicable)
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	US	 	61/027,382	 	2/8/2008
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	PCT	 	PCT/US2009/00077 3	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	US	 	12/866,706	 	11/15/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	AU	 	2009210656	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	CA	 	2,715,353	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	CN	 	200980111015.2	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	EP	 	097083873	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	HK	 	111094253	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	 	JP	 	2010-545885	 	2/6/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	 	US	 	61/027,360	 	2/8/2008

 

    	 	13	 

     

    

 

	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	PCT	 	PCT/US2009/00075 0	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER	 	US	 	12/866,710	 	11/10/2010
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	AU	 	2009210734	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	CA	 	2,715,329	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	CN	 	200980110139.9	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER	 	EP	 	09708292.9	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	HK	 	11109534J	 	2/6/2009
	 	 	 	 	 	 	 
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	 	JP	 	2010-545878	 	2/6/2009
	 	 	 	 	 	 	 
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	 	US	 	61/027,388	 	2/8/2008
	 	 	 	 	 	 	 
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	 	US	 	61/055/071	 	5/21/2008

 

    	 	14	 

     

    

 

	Patent	 	Country	 	
        Application No.

or Registration

No.

(as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	STABILIZED PICOPLATIN DOSAGE FORM	 	PCT	 	PCT/U52008/08076	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	US	 	12/635,517	 	12/10/2009
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR OVARIAN CANCER	 	US	 	12/635,534	 	12/10/2009
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR OVARIAN CANCER	 	US	 	12/781,599	 	5/17/2010
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR OVARIAN CANCER	 	PCT	 	PCT/US11/036855	 	5/17/2011
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	AU	 	2008295576	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	BR	 	P10811816-7	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	CA	 	2,691,115	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	CN	 	200880022248.0	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	EP	 	08828991.3	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	HK	 	10108170.3	 	6/27/2008

 

    	 	15	 

     

    

 

	 	 	 	 	Application No.

or Registration

No.	 	Application Filing

Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	STABILIZED PICOPLATIN DOSAGE FORM	 	ID	 	W-00201000277	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	ru	 	 	 	6/27/208
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	IN	 	7725/CHENP/2009	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	JP	 	20 10-5 14837	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	KR	 	10-2010-7001745	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	MX	 	MX/a12009/013835	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	RU	 	2010102096	 	6/27/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	TW	 	097124033	 	6/28/2008
	 	 	 	 	 	 	 
	STABILIZED PICOPLATIN DOSAGE FORM	 	UA	 	201000817	 	6/28/2008
	 	 	 	 	 	 	 
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	 	US	 	61/169,679	 	4/15/2009
	 	 	 	 	 	 	 
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	 	US	 	61/170,487	 	4/17/2009
	 	 	 	 	 	 	 
	HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	 	PCT	 	PCT/U52010/00735	 	3/11/2010

 

    	 	16	 

     

    

 

	 	 	 	 	Application No.	 	 
	 	 	 	 	or Registration	 	Application Filing
	 	 	 	 	No.	 	Date or Registration
	Patent	 	Country	 	(as applicable)	 	Date (as applicable)
	HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	 	US	 	13/264,343	 	10/13/2011
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	61/177,567	 	5/12/2009
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	PCT	 	PCT/U52010/34591	 	5/12/2010
	 	 	 	 	 	 	 
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	 	US	 	13/319,647	 	11/9/2011
	 	 	 	 	 	 	 
	USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER	 	US	 	61/177,571	 	5/12/2009
	 	 	 	 	 	 	 
	IMPROVED SYNTHESIS OF PICOPLATIN	 	US	 	61/186,526	 	6/12/2009
	 	 	 	 	 	 	 
	IMPROVED SYNTHESIS OF PICOPLATIN	 	PCT	 	PCT/US2010/38348	 	6/11/2010
	 	 	 	 	 	 	 
	IMPROVED SYNTHESIS OF PICOPLATIN	 	TW	 	099119171	 	6/11/2010
	 	 	 	 	 	 	 
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	US	 	61/311,169	 	3/5/2010
	 	 	 	 	 	 	 
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	US	 	61/345,442	 	5/17/2010
	 	 	 	 	 	 	 
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	PCT	 	PCT/U52011/02726 4	 	3/4/2011

 

    	 	17	 

     

    

 

	Patent	 	Country	 	
        Application No.

or Registration

No,

(as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	METHOD TO TREAT SMALL CELL LUNG CANCER	 	TW	 	100 1076 12	 	3/7/2011
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	US	 	61/345,451	 	5/17/2010
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	US	 	61/346,777	 	5/20/2010
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	PCT	 	PCT/1J52011/02726	 	3/4/2011
	 	 	 	 	 	 	 
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	 	TW	 	100107621	 	3/7/2011
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	PCT	 	PCT/1J52008/00320	 	3110/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	US	 	12/531,010	 	9/11/2009
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	CA	 	2,681,015	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	CN	 	200880015910.X	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	EP	 	08726698.7	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	HK	 	10107956.5	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	IN	 	5948/DELNP/2009	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	JP	 	2009-553600	 	3/10/2008
	 	 	 	 	 	 	 
	INHIBITORS OF FOCAL ADHESION KINASE	 	TW	 	97109125	 	3/14/2008

 

    	 	18	 

     

    

 

	Patent	 	Country	 	
        Application No.

or Registration

No.

(as applicable)
	 	Application Filing

Date or Registration

Date (as applicable)
	METHODS OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS	 	PCT	 	PCT/US2010/04535	 	8/12/2010
	 	 	 	 	 	 	 
	SYNTHESIS AND USE OF KINASE INHIBITORS	 	US	 	61/359,942	 	6/30/2010
	 	 	 	 	 	 	 
	SYNTHESIS AND USE OF KINASE INHIBITORS	 	PCT	 	PCT/US2011/04216	 	6/28/2011
	 	 	 	 	 	 	 
	ORAL FORMULATION OF 1UNASE INHIBITORS	 	US	 	61/359,694	 	6/29/2010
	 	 	 	 	 	 	 
	ORAL FORMULATION OF KINASE INHIBITORS	 	PCT	 	PCT/U52011/04216	 	6/28/2011

 

    	 	19Exhibit 10.8

 

ASSIGNMENT OF LICENSE AGREEMENT

 

This Assignment Agreement,
effective as of March 15, 2016 (the “Effective Date”), is entered into between Tallikut Pharmaceuticals, Inc. (“Tallikut”),
a corporation existing under the laws of Delaware, and Accelerated Pharma, Inc. (“API”), a corporation existing under
the laws of Delaware.

 

WHEREAS, pursuant
to that certain License Agreement between AnorMED Inc. (“AnorMED”) and NeoRx Corporation (“NeoRx”), dated April
2, 2004, as amended by that certain Amendment No. 1 to License Agreement, dated September 18, 2006, between AnorMED and Poniard
Pharmaceuticals, Inc., as successor-in-interest to NeoRx (“Poniard”) (as amended, the “License Agreement,”
a copy of which is attached hereto as Exhibit 1), Poniard obtained a license from AnorMED to certain patent rights, technical
data, and information related to picoplatin (also referred to as AMD473) (the “AnorMED Patents”);

 

WHEREAS, Encarta,
Inc. (“Encarta”) acquired all of Poniard’s right, title and interest in and to all assets related to picoplatin, including
Poniard’s licensed rights to the AnorMED Patents, pursuant to that certain Assert Purchase Agreement between Poniard (assignment
for the benefit of creditors), LLC and Encarta, dated June 20, 2013;

 

WHEREAS, Tallikut subsequently acquired
Encarta, including its licensed rights to the AnorMED Patents;

 

WHEREAS, AnorMED, including its
assets related to picoplatin, was acquired by Genzyme Corp., which was acquired by Sanofi;

 

WHEREAS, Tallikut sublicensed its
licensed rights to the AnorMED Patents to API pursuant to that certain Exclusive License Agreement dated June 17, 2014; and

 

WHEREAS, Tallikut desires to assign
the License Agreement, including its rights to the AnorMED Patents, to API;

 

NOW, THEREFORE, in consideration
of the mutual covenants and promises herein contained, the parties hereto agree as follows.

 

Section
1.        Tallikut warrants and represents that the License Agreement is in full force and effect and is fully assignable.
Tallikut further warrants and represents that rights in the License Agreement herein transferred are free of liens, encumbrances
or adverse claims. The License Agreement has not been modified (except to the extent of the above-referenced amendment) and remains
in effect pursuant to the terms contained therein. Tallikut hereby assigns its entire right, title, and interest in and to, and
its obligations under, the License Agreement to API (the “Assignment”).

 

Section
2.        API hereby accepts the Assignment, and agrees to assume, perform, and comply with and to be bound by all of the
terms, covenants, agreements, provisions, and conditions of the License Agreement as of the Effective Date.

 

    	Assignment of License Agreement	 	Page 1 of 2

     

    

 

Section
3.        Tallikut shall remain bound by any payment obligations to AnorMED under the License Agreement relating to the period
prior to the Effective Date, and Tallikut shall remain liable to AnorMED for any claims arising out of such rights prior to the
Effective Date.

 

Section
4.        Tallikut hereby represents and warrants that it has the full right to convey the right, title, and interest herein assigned
and that Tallikut has not executed and will not execute any agreement in conflict herewith.

 

Section 5.        Tallikut
hereby represents and warrants that it has received the necessary consent to assign the License Agreement, as required under Section
19.1 of the License Agreement.

 

Section
6.        This Assignment Agreement and the obligations of Tallikut and API hereunder
shall be binding upon and inure to the benefit of Tallikut and API and their respective successors and assigns, and may not be
modified or amended in any manner other than by a written agreement signed by the party to be charged therewith. Tallikut and
API agree to execute any and all other assignments, documents, certificates and other instruments as may at any time be deemed
reasonably necessary to further evidence or consummate this Assignment Agreement.

 

IN WITNESS WHEREOF, the parties have executed
this Assignment Agreement effective as of the Effective Date.

 

	TALL1KUT P ARMACEUTICALS, INC.	ACCELERATED PHARMA INC.

 

	By:	/s/ Fred Craves	 	By:	/s/ Michael Fonstein
	 	 	 	 	 
	Name:	Fred Craves	 	Name:	Michael Fonstein
	 	 	 	 	 
	Title:	Chairman of the Board	 	Title:	Chief Executive Officer

 

    	Assignment of LICENSE Agreement	 	Page 2 of 2

     

    

 

Exhibit 1

 

AMENDMENT NO. 1 TO

LICENSE AGREEMENT

 

THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT (this “Amendment”),
effective as of September 18, 2006 (the “Amendment Date”), is entered into between ANORMED INC, (“AnorMED”),
a corporation organized and existing under the laws of Canada and having an office at #200 - 20353 64th Ave, Langley,
BC Canada V2Y IN5, and PONIARD PHARMACEUTICALS, INC. (“Poniard”), a corporation organized and existing under
the laws of the State of Washington end having an office at 300 Elliott Avenue West, Suite 500, Seattle, WA 98119, with respect
to the following facts:

 

WHEREAS, AnorMED and Poniard (previously NeoRx
Corporation) entered into that License Agreement dated as of April 2, 2004 (the “License Agreement”).

 

WHEREAS, AnorMED and Poniard desire to amend
the License Agreement in certain respects, all on the terms and conditions set forth below.

 

NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants set forth below, the parties hereby amend the License Agreement and otherwise agree as follows:

 

1.     Payments.
In consideration of the rights granted hereunder, Poniard shall pay to AnorMED the following amounts at the times ramified:

 

		1.1.	On or before October 16, 2006, Poniard shall pay to AnorMED
the sum of five million U.S. dollars (US$5,000,000).

 

		1.2.	On or before March 31, 2007, Poniard shall pay to AnorMED
an additional sum of five million U.S. dollars (US$5,000.000).

 

2.     Territory.
In connection with the expansion of the Territory pursuant to Section 3.5 of this Amendment, the parties acknowledge and agree
that the provisions in the License Agreement regarding providing information or rights to AnorMED’s licensees outside of
the Territory, shall only apply with respect to any countries if and when excluded from the Territory in accordance with Section
4.2 (Decision Not to Commercialize) of the License Agreement.

 

3.     Amendments

 

		3.1.	The License Agreement is hereby amended by replacing all
uses of “NeoRx Corporation” with “Poniard Pharmaceuticals, Inc.”, and replacing all uses of the defined
term “NeoRx” with “Poniard.”

 

		3.2.	Section 1.1(v) of the License Agreement is hereby amended
by adding the following new sentence immediately following the end of Section 1.1(v):

 

     

     

    

 

As used in this Agreement, “end user”
shall mean, with respect to a Licensed Product, the first Person, that has not obtained from Poniard any license rights under Section
3.1 other than the right to use, to which such Licensed Product is sold or otherwise transferred in an arm’s-length, good
faith transaction.

 

		3.3.	Section 1.1(dd) of the License Agreement is hereby amended
and replaced in its entirety with the following;

 

(dd) “Sublicensee” shall
mean any Person who has obtained license rights from Poniard under the license granted to Poniard under Section 3.1, including,
without limitation, sublicensees of Poniard and its Affiliates, sublicensees of such sublicensees (i.e. subsublicensees), distributors
and any other Person who may sell or otherwise transfer Licensed Product to end users (as defined in Section 1.1(v)) of the Licensed
Product, in each case under such license rights;

 

and each occurrence of the term “sublicensee” and “sublicensees”
set out in the License Agreement is hereby replaced with the defined terms “Sublicensee” and “Sublicensees”,
respectively.

 

		3.4.	Section 1.1(ee) of the License Agreement is hereby amended
and replaced in its entirety with the following:

 

		(ee)	(intentionally omitted);

 

		3.5.	Section 1.1(gg) of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		(gg)	“Territory” shall mean world-wide;

 

		3.6.	Section 6.3 of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		6.3	Milestone Payments

 

In consideration of the license granted under Article 3,
Poniard shall pay to AnorMED the following milestone payments upon the first occurrence of each of the commercialization milestones
set forth below:

 

		(a)	[intentionally omitted];

 

		(b)	[intentionally omitted];

 

		(c)	[intentionally omitted];

 

		(d)	US$2,000,000 upon achieving Net Sales by Poniard and its
Affiliates of US$50,000,000 in the United States for any or all Licensed Products; and

 

     

     

    

 

		(e)	US$3,000,000 upon achieving Net Sales by Poniard and its
Affiliates of US$100,000,000 in the United States for any or all Licensed Products.

 

For purposes of this Section 6.3, “control”
in the definition of Affiliate shall mean direct or indirect beneficial ownership of 35% or greater interest in the income of a
Person or such other relationship as, in fact, constitutes actual control.

 

		3.7.	Section 6.4, subsection (a) of the License Agreement is
hereby amended and restated in its entirety as follows:

 

[intentionally omitted];

 

		3.8.	3.8 Section 6.4, subsection (b) of the License Agreement
is hereby emended and restated in its entirety as follows;

 

Each milestone payment to be made by Poniard under Subsections 6_3(d)
and 6.3(e) shall be made in cash, by certified cheque payable to the order of Marisa], or by bank transfer to the co-ordinates
given by AnorMED to Poniard.

 

		3.9.	Section 7.2 of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		7.2	Basic Royalty.

 

In consideration of the license granted under Article 3,
Poniard shall pay to AnorMED, without duplication, in respect of each Licensed Product:

 

		(a)	for all Patent Pending Counties where no Competition exists
and all Issued Patent Countries, a royalty on Net Sales of such Licensed Product by Poniard and its Affiliates and any Sublicenses
in each calendar year as follows:

 

		i.	five percent (5%) of the first one hundred million dollars
(US$100,000,000) of such Net Sales in the calendar year, calculated cumulatively among all Patent Pending Counties where no Competition
exists and all Issued Patent Countries, world-wide;

 

		ii.	six percent (6%) of such Net Sales in excess of the first
one hundred million dollars (US$100,000.000) but less than four hundred million dollars (US$400,000,000) in the calendar year,
where such amounts are calculated cumulatively among all Patent Pending Countries where no Competition exists and all Issued Patent
Counties, world-wide:

 

		iii.	eight Percent (8%) of such Net Sales in excess of the first
four hundred million dollars (US$400,000,000) but less than one billion dollars (US$ 1,000,000,000) in the calendar year, where
such amounts are calculated cumulatively among all Patent Pending Counties where no Competition exists and all Issued Patent Countries,
world-wide; and

 

		iv.	nine percent (9%) of such Net Sales in excess of one billion
dollars (USS1,000,000,000) in the calendar year, calculated cumulatively among all Patent Pending Counties where no Competition
exists and all Issued Patent Counties, world-wide; and

 

     

     

    

 

		(b)	for all Patent Pending Countries where Competition exists
and all Know-How Counties, a royalty on Net Sales of such Licensed Product by Poniard and its Affiliates and any Sublicensees
in each calendar year as follows

 

		i.	two and ono-half percent (2 1/2%) of the first one hundred
million dollars (US$100,000,000) of such Net Sales in the calendar year, calculated cumulatively among all Patent Pending Counties
where Competition exists and all Know-How Countries, world-wide;

 

		ii.	three percent (3%) of such Net Sales in excess of the
first one hundred million dollars (US$ 100,000,000) but less than four hundred million dollars (US$400,000,00) in the calendar
year, where such amounts are calculated cumulatively among all Patent Pending Countries where Competition exists and all Know-How
Countries, world-wide;

 

		iii.	four percent (4%) of such Net Sales in excess of the
first four hundred million dollars (US$400,000,000) but less than one billion dollars (US$1,000,000,000) in the calendar year,
where such amounts are calculated cumulatively among all Patent Pending Countries where Competition exists and all Know-How Countries,
world-wide; and

 

		iv.	four and one-half percent (4 1/2%) of such Net Sales
in excess alone billion dollars (US$1,000,000,000) in the calendar year, calculated cumulatively among all Patent Pending Counties
where Competition exists and all Know-How Counties, worldwide;

 

in each of Subsections 7.2(a) and 7.2(b), until, the later
of either:

 

		(c)	the date of expiration of the last Valid Claim within the
AnorMED Patents covering the Licensed Product in the country of manufacture or sale, as applicable; or

 

		(d)	the expiration of 10 years after First Commercial Sale
of such Licensed Product in the country of sale.

 

For the purposes of this Section 7.2:

 

		(e)	“Issued Patent Countries” shall mean any or
all countries in the Territory where the Licensed Product sold is covered by one or more Valid Claims within the AnorMED Patents
described in Paragraph 1.1(ii)(ii) of the definition of Valid Claim, either in the country of manufacture or in the county of
sale;

 

     

     

    

 

		(f)	“Patent Pending Countries” shall mean any or
all countries in the Territory where the Licensed Product sold is covered by one or more Valid Claims within the AnorMED Patents
described in Paragraph 1.1(ii)(i) of the definition of Valid Claim, but not a Valid Claim within the AnorMED Patents described
in Paragraph 1.1(ii)(ii) of the definition of Valid Claim either in the county of manufacture or in the country of sale; and

 

		(g)	“Know-How Countries” shall mean any or all
counties in the Territory where there is no Valid Claim either in the country of manufacture or in the country of sale, but AnorMED
Know How is necessary to make, have made, use, sell, offer for sale or import the Licensed Product, either in the country of manufacture
or in the country of sale; and

 

		(h)	“control” in the definition of Affiliate shall
mean direct and indirect beneficial ownership of 35% or greater interest in the income of a Person or such other relationship
as, in fact, constitutes actual control.

 

For purposes of clarification, no multiple royalties shall
be due or payable under this Section 7.2 because the sale or manufacture of any Licensed Product is or shall be covered by more
than one Valid Claim within the AnorMED Patents in the country of manufacture and/or the country of sale.

 

		3.10.	Section 73 of the License Agreement is hereby amended
and restated in its entirety as follows:

 

		7.3	Sublicensing Royalty

 

		(a)	In this Section 7.3:

 

(i)          “Development
Milestone Payments” shall mean all revenues, receipts, monies, milestone payments and research and development fees (in respect
of research and development fees. only to the extent that same are in excess of reimbursement for the direct costs and Indirect
Costs of research and development or pursuit of Regulatory Approval undertaken by Poniard or its Affiliates pursuant to a written
research or development plan), payments (including amounts received from the sale of shares in the capital stock of Poniard in
excess of the Current Market Nee for such shares), license fees and the fair market value of all other consideration, collected
or received by Poniard or its Affiliates whether by way of cash, equity, credit or any barter, benefit, advantage, or concession,
that are contingent upon the achievement of an event or objective pursuant to a written research or development plan, and not merely
the passage of time, and shall exclude amounts collected or received by Poniard or its Affiliates on account of Net Sales of Licensed
Products;

 

     

     

    

 

(ii)         “Indirect
Costs” shall mean costs incurred for the benefit of the Development Program or the commercialization of a Licensed Product,
excluding directly identified costs (direct costs), and including facility rental costs; utilities costs; laboratory and manufacturing
equipment depreciation; and salaries, vacation pay, sick leave pay, health insurance premiums, FICA taxes (or their equivalent)
and pension costs for employees, but only to the extent that such employees work benefits the Development Program or the commercialization
of a Licensed Product; and

 

(iii)        “Upfront
Cash Payments” shall mean all revenues, receipts, monies and research and development fees (in respect of research and development
fees, only to the extent that same are in excess of reimbursement for the direct costs and Indirect Costs of research and development
or pursuit of Regulatory Approval undertaken by Poniard or its Affiliates pursuant to a written research . or development plan),
payments (including amounts received from the sale of shares in the capital stock of Poniard in excess of the Current Market Price
for such shares), license fees and the fair market value of all other consideration, collected or received by Poniard or its Affiliates
whether by way of cash, equity, credit or any barter, benefit, advantage, or concession, and shall exclude Development Milestone
Payments and amounts collected or received by Poniard or its Affiliates on account of Net Sales of Licensed Products.

 

		(b)	In consideration of the license granted under Article 3,
Poniard shall pay to AnorMED:

 

(i)          in
respect of any agreement entered into by Poniard or its Affiliates prior to March 18, 2007 for the sublicensing to a Third Party
of any of its rights granted under Section 31, a royalty of ten percent (10%) of all Upfront Cash Payments and Development Milestone
Payments received by Poniard under such agreement; and

 

(ii)         in
respect of any agreement entered into by Poniard or its Affiliates during the period following March 18, 2007 but prior to September
18, 2007 for the sublicensing to a Third Party of any of its rights granted under Section 3.1, a royalty of five percent (5%) of
all Upfront Cash Payments received by Poniard under such agreement.

 

		3.11.	Section 8.7(a)(i) of the License Agreement is hereby
4mended and restated in its entirety as follows:

 

(i)          in
the ease of Poniard, records of all sales of Licensed Products in the Territory, which shall show the manufacturing, sales, use
and other disposition of Licensed Products in sufficient detail to determine the royalties payable to AnorMED pursuant to Section
7.2 and 7.3, if any and

 

     

     

    

 

		3.12.	Section 10.1(6) of the License Agreement is hereby amended
by replacing the words ‘Subsections 7.2(a), 7.2(b) and 7.2(c)” on the sixth line thereof with the words “Subsections
7.2(a) and 7.2(b)”, and replacing the words “Subsection 7.2(d)” on the tenth line thereof with the words “Subsection
7.2(b)”, so as to read

 

		(b)	At any time during the Term, Poniard, in Poniard's sole
discretion, may determine that any particular Patent within the AnorMED Patents in any particular country in the Territory should
not be prosecuted or maintained for legal or commercial reasons and in such emit, shall so notify Anent/MD. Upon receipt of such
notice, any Patents identified in such notice shall remain or he deemed to remain within the AnorMED Patents for the purposes
of the grant of rights by AnorMED to Poniard pursuant to Article3 of this Agreement and Poniard's obligations pursuant to Subsections
7.2(a) and 7.2(h) for the payment of royalties for any such Patents shall remain unchanged and continue at the royalty rate for
such Patent as of the date of Poniard's notice to AnorMED, provided that where the discontinuance of the prosecution or maintenance
of the Patent is due to reasons of lack of patentability, invalidity or unenforceability of the Patent, Poniard's obligations
pursuant to Subsection 7.1(3) for the payment of royalties for AnorMED Know-How shall apply. AnorMED, at AnorMED's cost and expense
and in AnorMED's sole discretion, may continue prosecution and/or maintenance of any particular Patent i4unti.6ed in such notice.

 

		4.	Miscellaneous. All terms used, bat not &fined,
herein shall have the respective meanings set forth in the License Agreement Except as otherwise expressly modified by this Amendment,
the License Agreement shall remain in full force and effect in accordance with its terms. This Amendment shall be governed by
the laws of the State of Washington and the United States of America applicable without regard to conflict of law provisions contained
therein. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument

 

IN WITNESS WHEREOF, the parties have executed this Amendment effective
as of the Amendment Date.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]